The members of the EPAD initiative are glad to announce that its Longitudinal Cohort Study has recruited its 2,000th research participant in Sheffield (UK) this 15th January. Congratulations to the EPAD team in Sheffield (pictured).
“Since we joined the project last year, patients in our area have been enthusiastic about the opportunities offered to them by participating in the EPAD project. As researchers and clinicians with many years of experience of research in Alzheimer’s disease, we have also been very enthusiastic about the possibilities that this programme offers. Myself and my team have been extremely excited about the endless possibilities for hypothesis testing that such a large number of patients with longitudinal monitoring and deep phenotyping offer to gain insight into the preclinical and prodromal features of Alzheimer’s disease”, said Annalena Venneri (principal investigator of the EPAD project in Sheffield).
The EPAD Longitudinal Cohort Study started the recruitment on May 2016 and is composed of individuals who do not have dementia and are already participating in different cohort studies and clinics across Europe. Their participation in the project involve standardised tests and follow-up over several years.
Currently, EPAD has 29 study sites up and running across 9 European countries (i.e. Belgium, France, Greece, Italy, Netherlands, Spain, Switzerland, Sweden and UK). We are pleased that Cliniques Universitaires Saint-Luc (Brussels, Belgium) became the latest addition to the EPAD family and recruited their first research participants.
EPAD is a Europe-wide collaboration aiming to improve the understanding of the early stages of Alzheimer’s disease. It combines knowledge and expertise from 39 organisations across multiple sectors from academia and industry, bringing together a wealth of experience to its activities and making it the largest ever public-private partnership in Alzheimer’s disease research.